For subcutaneous use in dogs only

Mineralocorticoid

Federal law (U.S.A.) restricts this drug to use by or on the order of a licensed veterinarian.

Desoxycorticosterone pivalate is a mineralocorticoid hormone. Chemically, desoxycorticosterone pivalate is 21-(2,2-dimethyl-1-oxopropoxy)-pregn-4-ene-3,20-dione.

The structural formula is:

Molecular Formula: C26H38O4

ZYCORTAL Suspension is a white aqueous suspension.

Each milliliter contains 25 mg of desoxycorticosterone pivalate. Inactive ingredients are 10.5 mg methylcellulose, 3 mg sodium carboxymethylcellulose, 1 mg polysorbate 60, 8 mg sodium chloride, 1 mg chlorocresol and water for injection (to 100%).

For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison's disease).

Prior to each use, thoroughly shake the vial to resuspend the product.

ZYCORTAL Suspension replaces the mineralocorticoid hormones only. Dogs with combined glucocorticoid and mineralocorticoid deficiency should also be treated with prednisone or prednisolone at an initial dosage of 0.2-0.4 mg/kg/day (0.1-0.2 mg/lb/day).

ZYCORTAL Suspension is intended for long-term administration at intervals and doses dependent upon individual response. Tailor the dose of ZYCORTAL Suspension and the concurrently administered glucocorticoid replacement therapy to the individual dog based on clinical response and normalization of Na+ and K+ concentrations.

Do not use ZYCORTAL Suspension in dogs that have previously had a hypersensitivity reaction to desoxycorticosterone pivalate.

Use ZYCORTAL Suspension with caution in dogs with congestive heart disease, edema, severe renal disease or primary hepatic failure. Desoxycorticosterone pivalate may cause polyuria, polydipsia, increased blood volume, edema and cardiac enlargement. Excessive weight gain may indicate fluid retention secondary to sodium retention.

Do not use desoxycorticosterone pivalate in pregnant dogs.

Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.

Any dog presenting with severe hypovolemia, dehydration, pre-renal azotemia and inadequate tissue perfusion ("Addisonian crisis") must be rehydrated with intravenous fluid (saline) therapy before starting treatment with ZYCORTAL Suspension.

The effectiveness of ZYCORTAL Suspension may be reduced if potassium-sparing diuretics, such as spironolactone, are administered concurrently.

One hundred fifty-two dogs were included in the field safety analysis. Adverse reactions are summarized in Table 2.

One dog with a pre-existing Grade III/VI heart murmur developed congestive heart failure 17 days after the first administration of ZYCORTAL Suspension and was removed from the study.

In addition to the adverse reactions reported during the field study, post-approval adverse drug experience reporting for desoxycorticosterone pivalate injectable suspension included reports of anaphylaxis and anemia.

To report suspected adverse events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dechra at (866) 933-2472.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

Desoxycorticosterone is a corticosteroid with primarily mineralocorticoid activity, similar to aldosterone. In the kidney, desoxycorticosterone causes sodium and chloride ion retention, and hydrogen and potassium ion excretion, creating an osmotic gradient. The osmotic gradient promotes water absorption from the renal tubules resulting in increased extracellular fluid volume, leading to blood volume expansion, improved venous return to the heart, and increased cardiac output.

After subcutaneous administration of 11 mg/kg body weight (five times the labeled starting/initial dose of 2.2 mg/kg) of ZYCORTAL Suspension, the plasma half-life (mean ± standard deviation) is approximately 17 ± 7 days, with a maximum concentration (Cmax) of 13.2 ± 5 ng/mL, and time to maximum concentration (Tmax) of 10 ± 3.5 days.

A double-blinded, multi-site, 180-day field study evaluated the effectiveness of ZYCORTAL Suspension compared to an FDA-approved desoxycorticosterone pivalate active control. One hundred fifty-two (152) dogs of various breeds, 0.5-12.4 years of age and weighing 0.95-61.2 kg were enrolled. One hundred thirteen (113) dogs were treated with ZYCORTAL Suspension and 39 dogs were treated with the active control. Both groups were administered an initial dose of 2.2 mg/kg. Subsequent doses administered and/or frequency of administration were adjusted according to the clinical needs of the dog.

A dog was considered a treatment success if it remained clinically normal or had improved clinical signs compared to baseline and the Na+ and K+ concentrations were within the reference range of the analyzer, or the Na+/K+ ratio was between 27-32. Success rates for ZYCORTAL Suspension were 86.2% and 88.3% on Days 90 and 180, respectively; success rates for the active control were 85.1% and 86.9% on Days 90 and 180, respectively.

The mean final dose for ZYCORTAL Suspension was 1.9 ± 0.27 mg/kg (range 1.2-2.5 mg/kg) and the mean final dose interval was 38.5 ± 12.5 days (range 20-99 days) with the majority of dogs having a dosing interval between 20 and 46 days.

In a laboratory study, ZYCORTAL Suspension was administered via subcutaneous injection to 32 Beagle dogs (four groups of 8 dogs each) at doses of 0, 1, 3 and 5 times the labeled starting dose (1× = 2.2 mg/kg), once every 21 days for 6 months, for a total of 9 injections. The volume injected in 3× and 5× dogs was equally divided between three and five sites, respectively. Dogs in the 1× group were dosed at a single injection site. Control dogs (0×) received subcutaneous injections of 0.9% sodium chloride at a volume equivalent to the 5× dose.

The most frequently noted abnormal clinical observations were injection site reactions in treated dogs, characterized by erythema and edema. Clinical pathology findings considered related to ZYCORTAL Suspension treatment included: decreased mean corpuscular volume in 3× and 5× groups; increased globulin concentrations in all treated groups; decreased potassium concentrations in all treated groups; increased sodium concentrations in all treated groups; decreased chloride concentrations in the 3× group; decreased blood urea nitrogen concentrations in all treated groups; and decreased urine specific gravity concentrations in all treated groups. Gross necropsy findings considered treatment-related included: subcapsular and cortical renal cysts, corresponding histologically with vascular tunica media hyperplasia; and irregular white plaques in the injection site subcutaneous tissue, corresponding histologically with granulomatous inflammation. Additional histology findings considered treatment-related included: chronic inflammation of the renal cortices, cortical tubular basophilia, cortical tubular dilation, glomerulopathy (3× and 5× groups), and adrenal gland vacuolation (zona glomerulosa).

Store at controlled room temperature 25°C (77°F) with excursions between 15-30°C (59-86°F) permitted. Do not freeze.

Use within 120 days of first puncture and puncture a maximum of 4 times.

ZYCORTAL Suspension is supplied in a clear glass vial with 4 mL (100 mg) desoxycorticosterone pivalate (25 mg/mL).

NADA 141-444, Approved by FDA

NDC 17033-382-04

Manufactured for:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211
(866) 933-2472

Manufactured in the United Kingdom.

© 2015 Dechra Ltd
ZYCORTAL is a trademark of Dechra Ltd; all rights reserved.

F1194

Zycortal®
Suspension

(desoxycorticosterone
pivalate injectable
suspension)

25 mg/mL

Mineralocorticoid

For subcutaneous use
in dogs only.

Caution: Federal law
restricts this drug to use
by or on the order of a
licensed veterinarian.

NADA 141-444

Approved by FDA

4 mL
Dechra